BANK OF MONTREAL /CAN/ - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.

Quarter-by-quarter ownership
BANK OF MONTREAL /CAN/ ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2021$913,000
-17.8%
359,381
-5.2%
0.00%
-100.0%
Q2 2021$1,111,000
+58.5%
379,081
+36.9%
0.00%
Q1 2021$701,000
+8662.5%
276,988
+6774.9%
0.00%
Q4 2020$8,000
+100.0%
4,0290.0%0.00%
Q3 2020$4,000
+33.3%
4,0290.0%0.00%
Q2 2020$3,0000.0%4,0290.0%0.00%
Q1 2020$3,000
-81.2%
4,029
-77.3%
0.00%
Q4 2019$16,000
+23.1%
17,734
+30.8%
0.00%
Q3 2019$13,00013,5590.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q2 2021
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 34,935,485$39,477,0003.01%
Raffles Associates 2,080,536$2,351,0002.51%
Defender Capital, LLC. 5,184,035$5,862,0002.30%
Prescott General Partners LLC 1,851,851$2,093,0000.16%
DAFNA Capital Management LLC 140,000$158,0000.04%
Fort Sheridan Advisors LLC 83,931$95,0000.03%
Long Focus Capital Management, LLC 215,000$243,0000.02%
XTX Topco Ltd 72,807$82,0000.02%
Ergoteles LLC 490,895$555,0000.02%
Beirne Wealth Consulting Services, LLC 45,000$51,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders